Switching to carfilzomib for multiple myeloma patients who can't tolerate bortezomib
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial is for people newly diagnosed with multiple myeloma who are having side effects from their first treatment with bortezomib. It tests switching to a different drug called carfilzomib to see if it works well with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with multiple myeloma.
- You have only received one first-line treatment that included bortezomib (like VRD, VTD, VCD, or PAD).
- You have had side effects from bortezomib, such as nerve pain, liver problems, diarrhea, or other non-blood-related issues that led to a dose change or stopping the drug.
- You are able to carry out daily activities with little or no help (ECOG score 0-2).
- You do not have serious heart, lung, or other health problems like uncontrolled high blood pressure, heart failure, or severe asthma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
This trial tests a new CAR-T cell treatment that targets two proteins (BCMA and CD19) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to other treatments and has spread to tissues outside the bone marrow.
This Phase 2 trial tests how well an oral treatment plan (cyclophosphamide and dexamethasone) combined with carfilzomib works in people whose multiple myeloma has come back or not responded. It may help shrink the myeloma and control symptoms after treatment with medicines like lenalidomide.
This Phase 1 study tests a carfilzomib-based treatment plan to help people with multiple myeloma collect enough stem cells for an autologous (using your own) stem cell transplant. It’s mainly about whether this mobilization approach works and is safe for you.
This trial tests if combining the drug ATRA with carfilzomib can help people with multiple myeloma whose cancer has come back or stopped responding to at least three prior treatments, including carfilzomib. The goal is to see if this new combination works better than carfilzomib alone.
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
Hear when a new Newly Diagnosed Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.